In the world economic growth, the Atorvastatin Calcium Industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Atorvastatin Calcium market size to maintain the average annual growth rate of XXX from XXX million $ in 2014 to XXX million $ in 2019, SMI analysts believe that in the next few years, Atorvastatin Calcium market size will be further expanded, we expect that by 2024, The market size of the Atorvastatin Calcium will reach XXX million $.
Atorvastatin calcium is a crystalline calcium salt that is insoluble in aqueous solutions of pH 4 and below. The American College of Cardiology and American Heart Association recommends the use of atorvastatin calcium as first-line therapy for the prevention of atherosclerotic cardiovascular disease in adults.
Increasing the prevalence of cardiovascular diseases is expected to boost the growth of the global atorvastatin calcium market over the forecast period. For instance, according to the American Heart Association's Heart and Stroke Statistics 2019 Update, around 48% of all adults in the U.S. suffered from some type of cardiovascular disease in 2016.
Moreover, a high incidence of dyslipidemia is also expected to aid in the growth of the market. For instance, according to the study, “Prevalence and risk factors for dyslipidemia among adults in rural and urban China: findings from the China National Stroke Screening and prevention project (CNSSPP)”, published in November 2019, the prevalence of dyslipidemia was 43.2% in the study population.
High prevalence of obesity in developed regions is expected to offer lucrative growth opportunities for players in the global atorvastatin calcium market. For instance, according to the Centers for Disease Control and Prevention, Behavioral Risk Factor Surveillance System, 2018, 71424.3 thousand people in the U.S. suffer from obesity.
Moreover, R&D related to atorvastatin calcium is also expected to aid in the growth of the market. For instance, in September 2019, researchers from Kyungpook National University, South Korea, reported encapsulation of the hydrophobic drug atorvastatin calcium into the solid dispersions with the use of hydrophilic polymer and a spray-drying technique.
However, the use of atorvastatin calcium is associated with some side effects, which are expected to hinder the growth of the market. The use of atorvastatin calcium may lead to myopathies, liver enzyme abnormalities, joint pain, and pain in the extremities.
Key Takeaways:
- Increasing prevalence of cardiovascular diseases to augment the growth of the global atorvastatin calcium market over the forecast period
- Major players in the market are focused on the approval and launch of new products to expand their product portfolio. For instance, in March 2019, Lupin Limited received the U.S. FDA approval for its Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg
- Major players operating in the global atorvastatin calcium market include Pfizer, Inc., DSM Sinochem Pharmaceuticals, Cadila Pharmaceuticals, Lupin Limited, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Morepen, Teva Pharmaceutical Industries, Apotex Pharmachem, Sandoz Inc., Mylan Pharmaceuticals Inc., Kremers Urban Pharmaceuticals Inc., ScieGen Pharmaceuticals, Inc., Zheijang Neo-Dankon Pharmaceutical, Ningbo Menovo Pharmaceuticals Group, Jialin Pharmaceutical, Henan Topfond Pharmaceutical Co., Ltd., Zhejiang Hisun Pharmacutical, Zhejiang Hongyuan Pharmaceutical, Hubei Yitai Pharmaceutical, and Jiangsu Hengrui Medicine
This Report covers the manufacturers' data, including: shipment, price, revenue, gross profit, interview record, business distribution, etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.
Besides, the report also covers segment data, including: type segment, industry segment, channel segment, etc. cover different segment market sizes, both volume, and value. It also covers different industry's clients information, which is very important for the manufacturers. If you need more information, please contact SMI
Section 1: Definition
Section (2 3): Manufacturer Detail
Pfizer
DSM Sinochem Pharmaceuticals
Cadila Pharmaceuticals
Sun Pharmaceutical Industries
Dr. Reddy's
Morepen
Teva Pharmaceutical Industries
Apotex Pharmachem
Sandoz Inc
Mylan Pharmaceuticals Inc.
Kremers Urban Pharmaceuticals Inc.
ScieGen Pharmaceuticals, Inc.
Zheijang Neo-Dankon Pharmaceutical
Ningbo Menovo Pharmaceuticals Group
Jialin Pharmaceutical
Topfond
Zhejiang Hisun Pharmacutical
Zhejiang Hongyuan Pharmaceutical
Hubei Yitai Pharmaceutical
Jiangsu Hengrui Medicine
Section 4: Region Segmentation
North America Country (United States, Canada)
South America
Asia Country (China, Japan, India, Korea)
Europe Country (Germany, UK, France, Italy)
Other Country (Middle East, Africa, GCC)
Section (5 6 7): Segmentation
Product Type Segmentation:
- Chemical Synthesis
- Biocatalysis
Industry Segmentation:
- Tablet (Including Dispersible Tablet and General Tablet)
- Capsule
Channel (Direct Sales, Distributor) Segmentation
Section 8: Trend (2019-2024)
Section 9: Product Type Detail
Section 10: Downstream Consumer
Section 11: Cost Structure
Section 12: Conclusion
Request Discount 
Inquire Before Buy
